Presentation is loading. Please wait.

Presentation is loading. Please wait.

MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. MGA271 mediates in vitro ADCC across a panel.

Published byАнтон Юсупов Modified over 4 years ago

Similar presentations

Presentation on theme: "MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. MGA271 mediates in vitro ADCC across a panel."— Presentation transcript:

1 MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. The ability of MGA271 to mediate ADCC was evaluated on B7-H3–positive cancer cell lines with resting PBMCs. A, LnCAP prostate adenocarcinoma; B, SK-MES-1 lung carcinoma; C, MDA-MB-468 breast adenocarcinoma; D, SW780 colon adenocarcinoma; E, ACHN renal cell carcinoma; F, HT-1197 bladder carcinoma; G, UACC-62 melanoma; H, renal cell carcinoma; I, B7-H3–negative Raji B cell lymphoma. Deryk Loo et al. Clin Cancer Res 2012;18: ©2012 by American Association for Cancer Research

Download ppt "MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. MGA271 mediates in vitro ADCC across a panel."

Similar presentations

Samir M. El-Moghazy, Nahed M. Eid, Sahar M. Abou-Seri and Shaimaa M. Abdel-Rahman * Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo.

Samir M. El-Moghazy, Nahed M. Eid, Sahar M. Abou-Seri and Shaimaa M. Abdel-Rahman * Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo.
A UNIQUE IN VIVO ASSAY FOR YOUR ONCOLOGY DRUG CANDIDATES Target Validation Efficacy and Toxicity Evaluation Arnaud Peyronnier Business Development Manager.

A UNIQUE IN VIVO ASSAY FOR YOUR ONCOLOGY DRUG CANDIDATES Target Validation Efficacy and Toxicity Evaluation Arnaud Peyronnier Business Development Manager.
Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.

Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.
Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.
SCLCs and LCNECs are sensitive to PARP inhibition in vitro.

SCLCs and LCNECs are sensitive to PARP inhibition in vitro.
سرطان الثدي Breast Cancer

سرطان الثدي Breast Cancer
Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,

Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,
Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.
Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant p53-null cells. Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant.

Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant p53-null cells. Acquired CIN attenuation through APC/C dysfunction in aneuploidy-tolerant.
Effect of quercetin on colony-forming abilities of prostate cancer cell lines with different aggressive potentials. Effect of quercetin on colony-forming.

Effect of quercetin on colony-forming abilities of prostate cancer cell lines with different aggressive potentials. Effect of quercetin on colony-forming.
The absence of ADCC by nivolumab in vitro.

The absence of ADCC by nivolumab in vitro.
Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.
SW fraction induces S phase arrest and apoptosis.

SW fraction induces S phase arrest and apoptosis.
Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.
Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.

Recognition of naturally processed HTLV-1 Tax protein derived from HAM patient's PBMC. A, HTLV-1 Tax protein content was evaluated by Western blot analysis.
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
Variation in dUTPase expression in cell lines.

Variation in dUTPase expression in cell lines.
Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.

Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.
Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.
In vitro binding and specificity of OTL78.

In vitro binding and specificity of OTL78.

Similar presentations

Ads by Google